Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | PQR309 |
Trade Name | |
Synonyms | PQR 309|PQR-309|Bimiralisib |
Drug Descriptions |
PQR309 (Bimiralisib) is a dual pan-PI3K and mTORC1/2 inhibitor, which blocks PI3K/mTOR signaling, potentially resulting in inhibition of tumor growth (PMID: 29066507). |
DrugClasses | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 |
CAS Registry Number | 1225037-39-7 |
NCIT ID | C111898 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ibrutinib + PQR309 | Ibrutinib PQR309 | 0 | 0 |
Panobinostat + PQR309 | PQR309 Panobinostat | 0 | 0 |
PQR309 | PQR309 | 0 | 4 |
PQR309 + Rituximab | PQR309 Rituximab | 0 | 0 |
PQR309 + Venetoclax | PQR309 Venetoclax | 0 | 0 |